Inmunobiogram Arthritis 2018-05-28T16:37:26+00:00

Inmunobiogram® for RHEUMATOID ARTHRITIS

BIOHOPE is developing a blood-based in vitro diagnosis test to personalize immunosuppressant therapy for Rheumatoid Arthritis under treatment with immunosuppressant drugs. This diagnostic kit is named Inmunobiogram® (IMBG) – Arthritis.

Inmunobiogram® is being studied in Rheumatoid Arthritis under a comprehensive clinical plan program, which includes a first proof of concept clinical study in 100 patients (BH-Arthritis) and a subsequent validation study.

“BH-Arthritis” is a clinical study which aims to evaluate the feasibility and potential clinical utility of a specifically-developed Inmunobiogram® for Rheumatoid Arthritis.

click here to see R&D context

Clic here to know the context of R&D

We expect BH- Arthritis clinical study to demonstrate:

  • Inmunobiogram-AR (IMBG-AR) will be feasible in patients with Rheumatoid Arthritis at various disease stages and clinical scenarios.

  • Inmunobiogram-AR (IMBG-AR) will offer as an output an in vitro potency evaluation of Immunosuppressant drugs (IMs) that will be correlated with sensitivity grades of the patient to a panel of IMs.

  • A significant proportion of patients with non-controlled RA will show low-sensitivity patterns in IMBG-AR to the medication they are taking.

This first-in-clinic study is to be done in collaboration with the Rheumatology Unit of Reina Sofía Hospital (Córdoba) and Maimonides Institute of Biomedical Research, and it has started in 2Q2018.